Theradaptive’s core technology is its AMP2 protein-engineering platform, which enables therapeutic proteins to be precisely bound to implants and tissues for localized, sustained delivery. The company’s lead product, OsteoAdapt, is an osteoinductive bone graft that has earned three FDA Breakthrough Device Designations and is currently under FDA PMA review for spinal and dental applications. OsteoAdapt is being evaluated in the OASIS Pivotal trial for spinal fusion and is designed to replace traditional allograft and synthetic alternatives in the $10 billion U.S. spine surgery market, of which biologics account for more than $2 billion. In a newly announced strategic partnership, Alphatec Holdings (ATEC) secured exclusive U.S. commercial rights to OsteoAdapt and will pay Theradaptive upfront and milestone payments plus perpetual royalties. The collaboration provides non-dilutive revenue potential and broad commercial reach for the product. Concurrently, Theradaptive opened a Series B financing round to fund completion of clinical trials, expand manufacturing, and scale its platform globally. Financial details of the Series B have not been disclosed, and the company has not released revenue or user figures.

Total raised

$27M

Funding rounds

3

Latest round

Grant

Latest activity

May 2024